These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12200696)

  • 21. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis.
    Chen ZH; Olopade OI; Savarese TM
    Mol Pharmacol; 1997 Nov; 52(5):903-11. PubMed ID: 9351982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
    Schmid M; Malicki D; Nobori T; Rosenbach MD; Campbell K; Carson DA; Carrera CJ
    Oncogene; 1998 Nov; 17(20):2669-75. PubMed ID: 9840931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of purines in human lymphoblast cells deficient in methylthioadenosine phosphorylase activity.
    Gordon RB; Blackwell K; Emmerson BT
    Biochim Biophys Acta; 1987 Jan; 927(1):1-7. PubMed ID: 3098299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas.
    Chow WA; Bedell V; Gaytan P; Borden E; Goldblum J; Hicks D; Slovak ML
    Cancer Genet Cytogenet; 2006 Apr; 166(2):95-100. PubMed ID: 16631464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characterization of 5'-deoxy-5'-methylthioadenosine phosphorylase-deficient mutant clones of murine lymphoma cell line R1.1.
    Kadariya Y; Nishioka J; Nakamura A; Kato-Nakazawa K; Nobori T
    Cancer Sci; 2003 Jun; 94(6):519-22. PubMed ID: 12824877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.
    Bertino JR; Waud WR; Parker WB; Lubin M
    Cancer Biol Ther; 2011 Apr; 11(7):627-32. PubMed ID: 21301207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma.
    Hellerbrand C; Mühlbauer M; Wallner S; Schuierer M; Behrmann I; Bataille F; Weiss T; Schölmerich J; Bosserhoff AK
    Carcinogenesis; 2006 Jan; 27(1):64-72. PubMed ID: 16081515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers.
    Nobori T; Takabayashi K; Tran P; Orvis L; Batova A; Yu AL; Carson DA
    Proc Natl Acad Sci U S A; 1996 Jun; 93(12):6203-8. PubMed ID: 8650244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased sensitivity to thiopurines in methylthioadenosine phosphorylase-deleted cancers.
    Coulthard SA; Redfern CP; Vikingsson S; Lindqvist-Appell M; Skoglund K; Jakobsen-Falk I; Hall AG; Taylor GA; Hogarth LA
    Mol Cancer Ther; 2011 Mar; 10(3):495-504. PubMed ID: 21282358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.
    Schmid M; Sen M; Rosenbach MD; Carrera CJ; Friedman H; Carson DA
    Oncogene; 2000 Nov; 19(50):5747-54. PubMed ID: 11126361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.
    Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H
    Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance.
    Li CF; Fang FM; Kung HJ; Chen LT; Wang JW; Tsai JW; Yu SC; Wang YH; Li SH; Huang HY
    Oncotarget; 2014 Nov; 5(22):11428-41. PubMed ID: 25426549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line.
    Christopher SA; Diegelman P; Porter CW; Kruger WD
    Cancer Res; 2002 Nov; 62(22):6639-44. PubMed ID: 12438261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma.
    Kim J; Kim MA; Min SY; Jee CD; Lee HE; Kim WH
    Genes Chromosomes Cancer; 2011 Jun; 50(6):421-33. PubMed ID: 21412930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of expression of MTAP in uncommon T-cell lymphomas.
    Bertino JR; Lubin M; Johnson-Farley N; Chan WC; Goodell L; Bhagavathi S
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):306-9. PubMed ID: 23040436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of gene expression profiles predicting tumor cell response to L-alanosine.
    Efferth T; Gebhart E; Ross DD; Sauerbrey A
    Biochem Pharmacol; 2003 Aug; 66(4):613-21. PubMed ID: 12906926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression and clinical significance of methylthioadenosine phosphorylase gene in patients with non-small cell lung cancer].
    Dai WM; Li BY; Yu CH; Chu XY; Zhang KT
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):907-9. PubMed ID: 15329275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Independent Loss of Methylthioadenosine Phosphorylase (MTAP) in Primary Cutaneous T-Cell Lymphoma.
    Woollard WJ; Kalaivani NP; Jones CL; Roper C; Tung L; Lee JJ; Thomas BR; Tosi I; Ferreira S; Beyers CZ; McKenzie RCT; Butler RM; Lorenc A; Whittaker SJ; Mitchell TJ
    J Invest Dermatol; 2016 Jun; 136(6):1238-1246. PubMed ID: 26872600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
    Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
    Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting
    Hu Q; Qin Y; Ji S; Shi X; Dai W; Fan G; Li S; Xu W; Liu W; Liu M; Zhang Z; Ye Z; Zhou Z; Yang J; Zhuo Q; Yu X; Li M; Xu X
    Cancer Res; 2021 Oct; 81(19):4964-4980. PubMed ID: 34385182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.